145 related articles for article (PubMed ID: 14756240)
1. Regulatory mechanism of osteoclast activation.
Nakamura I; Rodan GA; Duong LT
J Electron Microsc (Tokyo); 2003; 52(6):527-33. PubMed ID: 14756240
[TBL] [Abstract][Full Text] [Related]
2. Integrin-mediated signaling in the regulation of osteoclast adhesion and activation.
Duong LT; Rodan GA
Front Biosci; 1998 Aug; 3():d757-68. PubMed ID: 9682033
[TBL] [Abstract][Full Text] [Related]
3. Integrins and signaling in osteoclast function.
Duong LT; Lakkakorpi P; Nakamura I; Rodan GA
Matrix Biol; 2000 May; 19(2):97-105. PubMed ID: 10842093
[TBL] [Abstract][Full Text] [Related]
4. Involvement of alpha(v)beta3 integrins in osteoclast function.
Nakamura I; Duong LT; Rodan SB; Rodan GA
J Bone Miner Metab; 2007; 25(6):337-44. PubMed ID: 17968485
[TBL] [Abstract][Full Text] [Related]
5. Evidence that activation of ASIC1a by acidosis increases osteoclast migration and adhesion by modulating integrin/Pyk2/Src signaling pathway.
Li X; Ye JX; Xu MH; Zhao MD; Yuan FL
Osteoporos Int; 2017 Jul; 28(7):2221-2231. PubMed ID: 28462470
[TBL] [Abstract][Full Text] [Related]
6. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase.
Duong LT; Lakkakorpi PT; Nakamura I; Machwate M; Nagy RM; Rodan GA
J Clin Invest; 1998 Sep; 102(5):881-92. PubMed ID: 9727056
[TBL] [Abstract][Full Text] [Related]
7. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.
Carron CP; Meyer DM; Engleman VW; Rico JG; Ruminski PG; Ornberg RL; Westlin WF; Nickols GA
J Endocrinol; 2000 Jun; 165(3):587-98. PubMed ID: 10828842
[TBL] [Abstract][Full Text] [Related]
8. Integrin function in osteoclasts.
Rodan SB; Rodan GA
J Endocrinol; 1997 Sep; 154 Suppl():S47-56. PubMed ID: 9379137
[TBL] [Abstract][Full Text] [Related]
9. The type II collagen N-propeptide, PIIBNP, inhibits cell survival and bone resorption of osteoclasts via integrin-mediated signaling.
Hayashi S; Wang Z; Bryan J; Kobayashi C; Faccio R; Sandell LJ
Bone; 2011 Oct; 49(4):644-52. PubMed ID: 21708300
[TBL] [Abstract][Full Text] [Related]
10. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.
Nakamura I; Pilkington MF; Lakkakorpi PT; Lipfert L; Sims SM; Dixon SJ; Rodan GA; Duong LT
J Cell Sci; 1999 Nov; 112 ( Pt 22)():3985-93. PubMed ID: 10547359
[TBL] [Abstract][Full Text] [Related]
11. Interaction of osteopontin with osteoclast integrins.
Horton MA; Nesbit MA; Helfrich MH
Ann N Y Acad Sci; 1995 Apr; 760():190-200. PubMed ID: 7540373
[TBL] [Abstract][Full Text] [Related]
12. Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment.
Mercer B; Markland F; Minkin C
J Bone Miner Res; 1998 Mar; 13(3):409-14. PubMed ID: 9525341
[TBL] [Abstract][Full Text] [Related]
13. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis.
Dresner-Pollak R; Rosenblatt M
J Cell Biochem; 1994 Nov; 56(3):323-30. PubMed ID: 7876325
[TBL] [Abstract][Full Text] [Related]
14. Src kinase activity is essential for osteoclast function.
Miyazaki T; Sanjay A; Neff L; Tanaka S; Horne WC; Baron R
J Biol Chem; 2004 Apr; 279(17):17660-6. PubMed ID: 14739300
[TBL] [Abstract][Full Text] [Related]
15. Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts.
Faccio R; Grano M; Colucci S; Villa A; Giannelli G; Quaranta V; Zallone A
J Cell Sci; 2002 Jul; 115(Pt 14):2919-29. PubMed ID: 12082152
[TBL] [Abstract][Full Text] [Related]
16. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2.
Kwon JO; Jin WJ; Kim B; Kim HH; Lee ZH
Eur J Pharmacol; 2015 Dec; 768():189-98. PubMed ID: 26528796
[TBL] [Abstract][Full Text] [Related]
17. p130Cas, Crk-associated substrate, plays important roles in osteoclastic bone resorption.
Nagai Y; Osawa K; Fukushima H; Tamura Y; Aoki K; Ohya K; Yasuda H; Hikiji H; Takahashi M; Seta Y; Seo S; Kurokawa M; Kato S; Honda H; Nakamura I; Maki K; Jimi E
J Bone Miner Res; 2013 Dec; 28(12):2449-62. PubMed ID: 23526406
[TBL] [Abstract][Full Text] [Related]
18. Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells.
Nakamura I; Tanaka H; Rodan GA; Duong LT
Endocrinology; 1998 Dec; 139(12):5182-93. PubMed ID: 9832459
[TBL] [Abstract][Full Text] [Related]
19. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption.
Ross FP; Chappel J; Alvarez JI; Sander D; Butler WT; Farach-Carson MC; Mintz KA; Robey PG; Teitelbaum SL; Cheresh DA
J Biol Chem; 1993 May; 268(13):9901-7. PubMed ID: 8486670
[TBL] [Abstract][Full Text] [Related]
20. Linarin and its aglycone acacetin abrogate actin ring formation and focal contact to bone matrix of bone-resorbing osteoclasts through inhibition of αvβ3 integrin and core-linked CD44.
Kim SI; Kim YH; Kang BG; Kang MK; Lee EJ; Kim DY; Oh H; Oh SY; Na W; Lim SS; Kang YH
Phytomedicine; 2020 Dec; 79():153351. PubMed ID: 32987362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
